Piper Sandler resumed coverage on AbbVie with a new price target
$ABBV
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler resumed coverage of AbbVie with a rating of Overweight and set a new price target of $231.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2025 | $231.00 | Overweight | Piper Sandler |
| 8/7/2025 | $214.00 | Neutral → Outperform | Daiwa Securities |
| 5/14/2025 | $205.00 | Buy → Neutral | Citigroup |
| 4/22/2025 | $210.00 | Overweight | Cantor Fitzgerald |
| 12/10/2024 | $191.00 | Neutral | BofA Securities |
| 12/5/2024 | $180.00 | Outperform → Neutral | Daiwa Securities |
| 11/22/2024 | $206.00 | Market Perform → Outperform | Leerink Partners |
| 11/15/2024 | $205.00 | Outperform | Wolfe Research |
Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:
Building on the brand's 20-year legacy and real-world experience, the original BOTOX® Cosmetic continues to be the most researched and requested product of its kind.1,2BOTOX® Cosmetic is trusted by aesthetic providers with 95% of specialists choosing it for themselves, their friends, and family.3This campaign is BOTOX® Cosmetic's largest ever, appearing across national linear and connected TV, digital, social, and out-of-home.IRVINE, Calif., Sept. 9, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced a new chapter for BOTOX® Cosmetic with the debut of "The One & Only" campaign, a national, multichannel marketing initiative that champions self-expression
NORTH CHICAGO, Ill., Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable November 14, 2025, to stockholders of record at the close of business on October 15, 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We
First-of-its-kind report is available at www.naturallyyouwithHA.com Deep dive into category education and data on HA injectable fillers and the natural-looking results they can achieveIRVINE, Calif., Sept. 3, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, has launched the "Naturally You with Injectable Hyaluronic Acid Fillers" campaign, aimed to providing clear, factual education about HA injectable fillers. This initiative focuses on correcting misinformation to elevate understanding and celebrate the safe, natural-looking outcomes possible with hyaluronic acid injectable fillers. "Our goal with Naturally You with Injectable Hyaluronic Acid Fillers campaign is to set the recor
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
3/A - AbbVie Inc. (0001551152) (Issuer)
Piper Sandler resumed coverage of AbbVie with a rating of Overweight and set a new price target of $231.00
Daiwa Securities upgraded AbbVie from Neutral to Outperform and set a new price target of $214.00
Citigroup downgraded AbbVie from Buy to Neutral and set a new price target of $205.00
144 - AbbVie Inc. (0001551152) (Subject)
144 - AbbVie Inc. (0001551152) (Subject)
144 - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme
NORTH CHICAGO, Ill., Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable November 14, 2025, to stockholders of record at the close of business on October 15, 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We
Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.631 Billion, an Increase of 9.5 Percent on a Reported Basis, or 9.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.423 Billion; Global Rinvoq Net Revenues Were $2.028 Billion; Global Humira Net Reven
NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –